We are live on
!
Find out more
Parallel Advisors Portfolio holdings
AUM
$6.56B
Turnover
11.49%
1-Year Est. Return
32.24%
This Fund
S&P 500
This Quarter
Est. Return
+8.88%
1 Year Est. Return
+32.24%
3 Year Est. Return
+108.68%
5 Year Est. Return
+114.41%
10 Year Est. Return
–
AUM
$5B
AUM Growth
+$569M
(+13%)
Cap. Flow
+$104M
Cap. Flow
% of AUM
2.08%
Top 10 Holdings %
Top 10 Hldgs %
38.84%
Holding
3,762
New
251
Increased
1,450
Reduced
1,277
Closed
224
Avg Time Held Equity + Options
4.7
years
Top 10 Avg Time Held Equity + Options
2.9
years
Top 20 Avg Time Held Equity + Options
3.8
years
Avg Time Held Equity only
4.7
years
Top 10 Avg Time Held Equity only
2.9
years
Top 20 Avg Time Held Equity only
3.8
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares Core S&P 500 ETF
IVV
|
+$18.4M |
| 2 |
iShares Core S&P Total US Stock Market ETF
ITOT
|
+$9.77M |
| 3 |
BlackRock US Equity Factor Rotation ETF
DYNF
|
+$5.48M |
| 4 |
Microsoft
MSFT
|
+$4.93M |
| 5 |
Vanguard S&P 500 ETF
VOO
|
+$4.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Corcept Therapeutics
CORT
|
+$7.34M |
| 2 |
Starbucks
SBUX
|
+$4.7M |
| 3 |
iShares California Muni Bond ETF
CMF
|
+$3.3M |
| 4 |
Invesco S&P 500 Equal Weight ETF
RSP
|
+$2.63M |
| 5 |
Vanguard Morningstar Small-Cap ETF
VB
|
+$1.7M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 46.71% |
| 2 | Technology | 17.21% |
| 3 | Healthcare | 9.68% |
| 4 | Financials | 7.2% |
| 5 | Communication Services | 5.16% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
3401
Neuropace
NPCE
$431M
| $167 | ﹤0.01% |
15
-4
| -21% | -$50 |
2025 Q1
1 quarter
|
|
3402
Atlanticus Holdings
ATLC
$1.38B
| $164 | ﹤0.01% |
+3
| New | +$156 |
2025 Q2
0 quarters
|
|
3403
Amarin Corp
AMRN
$245M
| $162 | ﹤0.01% |
10
| – | – |
2018 Q4
26 quarters
|
|
3404
DELISTED
Origin Materials
ORGN
| $161 | ﹤0.01% |
11
| – | – |
2021 Q2
16 quarters
|
|
3405
State Street SPDR S&P 600 Small Cap Value ETF
SLYV
$4.67B
| $160 | ﹤0.01% |
+2
| New | +$152 |
2025 Q2
0 quarters
|
|
3406
Altimmune
ALT
$449M
| $155 | ﹤0.01% |
40
| – | – |
2021 Q1
17 quarters
|
|
3407
Iovance Biotherapeutics
IOVA
$6.44B
| $148 | ﹤0.01% |
86
| – | – |
2020 Q2
20 quarters
|
|
3408
QuinStreet
QNST
$895M
| $145 | ﹤0.01% |
+9
| New | +$144 |
2025 Q2
0 quarters
|
|
|
BSLK
3409
DELISTED
Bolt Projects Holdings
BSLK
| $141 | ﹤0.01% |
+50
| New | +$221 |
2025 Q2
0 quarters
|
|
3410
Angi Inc
ANGI
$248M
| $137 | ﹤0.01% |
9
+2
| +29% | +$29 |
2025 Q1
1 quarter
|
|
3411
Teads Holding Co
TEAD
$41.2M
| $134 | ﹤0.01% |
54
+17
| +46% | +$51 |
2025 Q1
1 quarter
|
|
3412
Invesco DB US Dollar Index Bullish Fund
UUP
$463M
| $134 | ﹤0.01% |
+5
| New | +$138 |
2025 Q2
0 quarters
|
|
3413
State Street SPDR S&P Metals & Mining ETF
XME
$3.96B
| $134 | ﹤0.01% |
2
| – | – |
2020 Q3
19 quarters
|
|
3414
Editas Medicine
EDIT
$349M
| $132 | ﹤0.01% |
60
| – | – |
2022 Q2
12 quarters
|
|
3415
SI-BONE Inc
SIBN
$873M
| $132 | ﹤0.01% |
7
-20
| -74% | -$332 |
2024 Q4
2 quarters
|
|
3416
iShares Future Exponential Technologies ETF
XT
$3.97B
| $131 | ﹤0.01% |
+2
| New | +$119 |
2025 Q2
0 quarters
|
|
3417
Kalaris Therapeutics
KLRS
$50.7M
| $131 | ﹤0.01% |
49
| – | – |
2022 Q1
13 quarters
|
|
3418
BlackRock Income Trust
BKT
$310M
| $129 | ﹤0.01% |
+11
| New | +$127 |
2025 Q2
0 quarters
|
|
3419
Calumet Specialty Products
CLMT
$5.06B
| $126 | ﹤0.01% |
+8
| New | +$102 |
2025 Q2
0 quarters
|
|
3420
Investar Holding Corp
ISTR
$393M
| $125 | ﹤0.01% |
6
| – | – |
2022 Q4
10 quarters
|
|
3421
Concentra Group Holdings
CON
$4.78B
| $123 | ﹤0.01% |
6
-68
| -92% | -$1.45K |
2024 Q4
2 quarters
|
|
3422
Tempest Therapeutics
TPST
$10.7M
| $122 | ﹤0.01% |
18
| – | – |
2024 Q2
4 quarters
|
|
3423
Torrid Holdings
CURV
$237M
| $121 | ﹤0.01% |
41
| – | – |
2025 Q1
1 quarter
|
|
3424
Globalstar
GSAT
$10.7B
| $118 | ﹤0.01% |
5
| – | – |
2024 Q4
2 quarters
|
|
3425
Aurora Cannabis
ACB
$264M
| $114 | ﹤0.01% |
+27
| New | +$131 |
2025 Q2
0 quarters
|
|
Similar funds
Parallel Advisors's Q2 2025 Portfolio in Review
As of Q2 2025, Parallel Advisors held 3,762 positions worth $5B, up 13% from $4.43B the previous quarter. Its ten largest holdings account for 39% of the portfolio.
Parallel Advisors's Q2 2025 filing shows 251 new, 1,450 increased, 1,277 reduced and 224 closed positions. Its largest new stake was Vanguard 0-3 Month Treasury Bill ETF: 32,722 shares worth $2.47M. The largest sale was Corcept Therapeutics, an estimated $7.34M.
By sector, the portfolio is most concentrated in Miscellaneous at 47% of assets, down from 47% a quarter earlier, followed by Technology and Healthcare.
- Parallel Advisors's largest Q2 2025 buy was Vanguard 0-3 Month Treasury Bill ETF: 32,722 shares worth $2.47M.
- Parallel Advisors added most to iShares Core S&P 500 ETF in Q2 2025, an estimated $18.4M increase.
- Parallel Advisors's biggest Q2 2025 reduction was Corcept Therapeutics, cutting an estimated $7.34M.
- Parallel Advisors fully exited Discover Financial Services in Q2 2025, selling an estimated $1.22M.
- Parallel Advisors's ten largest holdings make up 39% of its $5B portfolio in Q2 2025.
- Parallel Advisors opened 251 new positions and closed 224 in Q2 2025.
- Parallel Advisors's portfolio value rose 13% quarter-over-quarter to $5B.
Based on Parallel Advisors's 13F filing for Q2 2025, filed 8 Jul 2025.